

Keywords: costs; hospital; population-based data; staging

Cost of care for cancer patients in England: evidence from population-based patient-level data

Mauro Laudicella^{*1}, Brendan Walsh¹, Elaine Burns² and Peter C Smith³

¹School of Health Sciences, City University London, London EC1V 0HB, UK; ²Department of Surgery and Cancer, Imperial College London, St Mary's Campus, Imperial College London, London W2 1NY, UK and ³Business School, Imperial College London, Tanaka Building, South Kensington Campus, London SW7 2AZ, UK

Background: Health systems are facing the challenge of providing care to an increasing population of patients with cancer. However, evidence on costs is limited due to the lack of large longitudinal databases.

Methods: We matched cost of care data to population-based, patient-level data on cancer patients in England. We conducted a retrospective cohort study including all patients age 18 and over with a diagnosis of colorectal (275 985 patients), breast (359 771), prostate (286 426) and lung cancer (283 940) in England between 2001 and 2010. Incidence costs, prevalence costs, and phase of care costs were estimated separately for patients age 18–64 and ≥ 65 . Costs of care were compared by patients staging, before and after diagnosis, and with a comparison population without cancer.

Results: Incidence costs in the first year of diagnosis are noticeably higher in patients age 18–64 than age ≥ 65 across all examined cancers. A lower stage diagnosis is associated with larger cost savings for colorectal and breast cancer in both age groups. The additional costs of care because of the main four cancers amounts to £1.5 billion in 2010, namely 3.0% of the total cost of hospital care.

Conclusions: Population-based, patient-level data can be used to provide new evidence on the cost of cancer in England. Early diagnosis and cancer prevention have scope for achieving large cost savings for the health system.

Many high-income countries, including England and the United States, are facing the challenge of providing care to an ever increasing population of patients with cancer (Sullivan *et al*, 2011). There are currently 1.8 million people living in England with a cancer diagnosis (Maddams *et al*, 2012). According to the latest projections more than one in three people in England will develop cancer in their lifetime and there will be an estimated 3 million people living with cancer in 2030 in England, due to increasing incidence and improving survivals (National Audit Office, 2015). These trends are expected to increase pressure on the budget of the National Health Service (NHS).

Evidence on the cost of cancer should be one of the main pillars supporting policymakers in achieving the best value for money and realise an efficient allocation of public resources across different

services and pathways of care. However, there is a dearth of evidence due to the lack of large databases collecting information on the cost of care accessed by patients over a sufficiently long period of time (National Audit Office, 2015). In England, current evidence is based on a limited number of patients treated in a restricted number of hospital sites (Hall *et al*, 2015), or is based on predicted pathways of care (Incisive Health, 2014). A number of studies used aggregated utilisation and cost data (Martin *et al*, 2008; Luengo-Fernandez *et al*, 2013; Incisive Health, 2014), which may affect the accuracy of estimates and limit the scope for analysis. Some authors deem the shortage of health economic studies to be a major contributor to the increasing cancer costs in England and other developed countries (Sullivan *et al*, 2011).

*Correspondence: Dr M Laudicella; E-mail: Mauro.Laudicella.1@city.ac.uk

Received 15 December 2015; revised 19 February 2016; accepted 3 March 2016; published online 12 April 2016

© 2016 Cancer Research UK. All rights reserved 0007–0920/16



In USA, the availability of the SEER-Medicare database has empowered researchers and allowed for increased evidence on the direct costs and economic costs of cancer in the past 20 years (Brown *et al*, 1999, 2002; Warren *et al*, 2008; Yabroff *et al*, 2008a, b, 2009, 2011; Basu and Manning, 2010). The USA experience highlights the potential of using population-based, patient-level databases in investigating a wide range of topics on the cost of cancer and in producing evidence to inform policymakers and the wider public. Although SEER-Medicare provides granular data on health-care utilisation and the costs of care, data are available only for a proportion of the population in USA age 65 and over. A recent study from New Zealand using population-based, patient-level data found higher costs in the age groups under 65 (Blakely *et al*, 2015).

In this study, we generate a new database for the analysis of the cost of cancer in England similar to the SEER-Medicare in the United States by matching data on the cost of care to data from all English cancer registries and hospital administrative databases. We use the new database to estimate incidence and prevalence costs of cancer in England and compare patterns of care costs in patients age 18–64 and ≥ 65 years old. The use of population-based, patient-level data allows us to disaggregate our estimates by phases of care and by stage at diagnosis, and to compare the direct cost of care in patients with and without cancer in the whole population of England. To the extent of our knowledge, this is the first time that such an analysis is made using population-based, patient-level data in England.

METHODS AND MATERIALS

Data sources. Our study includes data from three main sources: the National Cancer Data Repository (NCDR); Hospital Episode Statistics (HES); and the National Schedules of Reference Costs (NSRC). The NCDR provides information on the characteristics of patients, including tumour site, age, date of cancer diagnosis and date of death. HES collects information on patients' utilisation of hospital inpatient and outpatient care for all NHS patients in England; the few non-NHS patients account for <1% of total hospital income. Our data extract includes all episodes of care generated by patients in our sample before and after their cancer diagnosis between 2001 and 2010 (Supplementary Appendix 1). Finally, the NSRC includes information on the cost of all inpatient and outpatient services accessed by NHS patients. All NHS hospitals are mandated to report the cost of every service delivered to their patients at the end of the fiscal year. Cost data are disaggregated at the level of HRG (Healthcare Resource Group) making special adjustments for patients' type of admission, length of stay and access to special services, such as renal dialysis, chemotherapy, radiotherapy and rehabilitation. A detailed description of the NSRC data is included in Supplementary Appendix 2; the procedure followed to match NSRC with HES data is described in Supplementary Appendix 3.

Patients. We considered all individuals with a recorded diagnosis of colorectal cancer (ICD-10 code: C18, C19 and C20), breast cancer (C50), prostate cancer (C61) or lung cancer (C33 and C34) in the cancer registries of England between 1 January 2001 and 31 December 2010. We excluded individuals with age less than 18, or with a previous history of cancer, and males with breast cancer. We further excluded patients reported to have died with improper death certificate (DCO) registrations in line with previous work (Coupland *et al*, 2011). Our final sample included 275 985 colorectal cancer patients, 359 771 breast cancer patients, 286 426 prostate cancer patients and 283 940 lung cancer patients.

Outcome measures. The primary outcome measures of this study were incidence costs, phase of care costs and prevalence costs. The analysis is based on the cost of hospital activity fixed in 2010.

Incidence costs. Incidence costs are defined as the costs of delivering care to a homogeneous cohort of patients fixed in the year of their diagnosis and followed up for a number of years. In every year following the diagnosis, incidence costs include only patients who survive the previous year. Although we have registry data from 2001 to 2010, we have accurate costing data from 2006 to 2010 only. We extend the time window for cost analysis by including all cohorts diagnosed between 2001 and 2007 using similar methods to previous work (Brown *et al*, 1999, 2002). Firstly, we defined a starting cohort of patients diagnosed with cancer in 2007 and follow these patients for up to 3 years post diagnosis and 1 year prior. Secondly, we estimate 4–9-year incidence costs using hospital activity generated in 2010 by patients diagnosed between 2001 (9-year incidence cost) and 2006 (4-year incidence cost).

We used inverse probability weights (IPWs) (Hirano and Imbens, 2001; Wooldridge, 2007) to adjust for the potential differences between patients in the 2007 cohort and patients in the 2001–2006 cohorts. IPWs allow for greater weight to be given to the cost estimates of individuals who have similar characteristics to the 2007 cohort. Similarly, we extended our incidence costs up to 3 years before diagnosis using patients diagnosed in 2008 and 2009. IPWs were calculated from the propensity scores of a set of logistic regressions estimated over the differences between the 2007 and other cohorts. The set of examined covariates include: age; gender; deprivation; strategic health authority of residence; surgery in first 12 months; and number of hospital admissions in first 12 months. Little difference was observed between the 2007 diagnosis cohort and other cohorts.

Phase of care costs. We identified three distinct phases of care by examining patients with increasing survival times similarly to other studies (Brown *et al*, 1999; Yabroff *et al*, 2008a, 2009):

- The initial phase: the first 6 months immediately following diagnosis.
- The terminal phase: the final 12 months of life.
- The continuum phase: the time period between the initial and terminal phase.

In patients surviving no longer than 12 months (e.g., a large share of lung cancer patients), all costs were allocated to the terminal phase. To enter the initial phase, a patient must survive at least 13 months, and to enter the continuum phase, a patient must survive at least 19 months.

Prevalence costs. Prevalence costs provide a snapshot of the total costs delivered to all patients in a specific calendar year and include patients at different points after diagnosis. Prevalence costs are useful to monitor resources used by patients with a similar cancer and to plan for appropriate resource allocation in the future. Prevalence costs were estimated for 2010 by including only patients who were diagnosed within the previous 5 years (2006–2010). Costs were estimated for each phase of care (initial, continuum or terminal).

As this population of patients would still consume health care if free from cancer, we also compare cancer prevalence costs with the costs of care in a similar population without cancer. To this end, we used data on 'all' inpatient and outpatient admissions in England in 2010, data from Census 2011 and a simple standardisation technique. Firstly, we calculated the total cost of care accessed by 'all' patients aging 18 and over in 2010 (excluding patients with cancer and their costs) using the same methods for costing cancer patients and described in Supplementary Material.

Secondly, we calculated the average cost of care by 5-year age groups by dividing the total cost in each age group by the total population in each age group. Finally, we multiply the average costs in each age group by the total population of cancer patients in that group.

RESULTS

Patient average incidence costs. Table 1 reports the characteristics of patients in our sample separately for patients age 18–64 and ≥ 65 years old. The latter age group account for a substantial share of the population affected by the main four cancers: 73.3% of colorectal; 44.3% of breast; 77.4% of prostate; and 74.7% of lung cancer patients. Patients age 18–64 have a higher probability of receiving surgery within 12 month of their diagnosis and also surviving the first year after diagnosis. Cancer staging was missing in 24.5% of colorectal and 54.7% of breast cancer patients and imputed following methods described in Supplementary Appendix 4. Staging was missing for a large majority of patients with prostate and lung cancer; hence, we did not report it.

Table 2 reports average incidence costs per patient for patients age 18–64 and ≥ 65 , 3 years before and 9 years after their diagnosis. Costs of care are relatively small 2–3 years pre-diagnosis across all cancers and age groups and range from £162 per year for a prostate cancer patient age 18–64 to £542 per year for a lung

cancer patient age ≥ 65 . Costs start growing 1 year before diagnosis ranging between £484 (breast cancer age 18–64) and £1979 (lung cancer age ≥ 65) and peak in the year of diagnosis with marked differences between age groups. Costs in the year of the diagnosis reaches £17 241 per patient age 18–64 and £14 776 per patient age ≥ 65 in colorectal cancer, £11 109 and £7788 in breast cancer, £5171 and £4699 in prostate cancer and £12 083 and £9061 in lung cancer patients, respectively. Costs reduce in the years following the diagnosis but remain substantially higher than their pre-diagnosis level with patients age 18–64 now experiencing smaller costs as compared with patients age ≥ 65 .

Table 3 reports average incidence costs per patient for patients diagnosed with lower stage cancer (stage 1–2) and patients diagnosed with higher stage cancer (stage 3–4) for colorectal and breast cancer. Costs are calculated separately for patients age 18–64 and ≥ 65 and the difference in costs between lower and higher stage diagnoses is also reported. We were able to examine patients with colorectal and breast cancer only, since staging is not reported in a sufficient number of prostate or lung cancer patients. An early diagnosis is associated with lower costs in patients with colorectal and breast cancer both in patients age 18–64 and ≥ 65 . However, the potential cost savings associated with an early diagnosis are greater in patients age 18–64 than in patients age ≥ 65 . In colorectal cancer, lower stage diagnosis is associated with –£4276 cost per patient age 18–64 in the first year of diagnosis (–22.3% first year costs) as compared with –£1215 cost per patient age

Table 1. Patients' characteristics in selected cancer sites, 2001–2010

	Colorectal		Breast		Prostate		Lung	
	18–64	≥ 65	18–64	≥ 65	18–64	≥ 65	18–64	≥ 65
Total patients	275 985		359 771		286 426		283 940	
Patients age ≥ 65	73.3%		44.3%		77.4%		74.7%	
Age group	18–64	≥ 65	18–64	≥ 65	18–64	≥ 65	18–64	≥ 65
Share female	41.5%	46.4%	100.0%	100.0%	0.0%	0.0%	43.3%	42.1%
Average age	55.6	77.1	52.2	76.4	59.2	75.4	57.2	76.4
Stages 1–2	45.8%	52.0%	88.2%	83.5%	—	—	—	—
Share in most deprived quintile	17.2%	16.2%	14.9%	15.0%	13.5%	13.8%	28.6%	25.2%
12 month survival	83.1%	65.8%	97.7%	87.8%	97.4%	88.3%	37.1%	25.4%
Surgery in the first 12 months ^a	60.7%	52.2%	77.6%	59.0%	22.0%	4.3%	12.6%	6.9%

^aSurgery was defined using the following OPCS-4 codes: colorectal (H04, H05, H06, H07, H08, H09, H10, H11 and H33); breast (B27 and B28); prostate (M611, M614, M618 and M619); lung (E391, E398, E399, E441, E461, E541, E542, E543, E544, E545, E548, E549, E552, E554, E559, E574, E578, E595 and T013).

Table 2. Average incidence costs per patient in selected cancer sites. Incidence costs are defined as the total cost of care delivered to all patients who are alive at the beginning of the considered period

	Colorectal (2010 £)		Breast (2010 £)		Prostate (2010 £)		Lung (2010 £)	
	18–64	≥ 65	18–64	≥ 65	18–64	≥ 65	18–64	≥ 65
3 Years pre	201	435	165	439	162	375	344	544
2 Years pre	262	471	183	398	224	517	310	542
1 Year pre	1023	1760	484	1126	715	1430	1337	1979
1 Year	17 241	14 776	11 109	7788	5171	4699	12 083	9061
2 Years	5014	4231	3676	2675	1965	2705	4540	4320
3 Years	3687	3403	2176	2270	1927	2598	4002	3945
4 Years	2927	2821	1782	2283	1484	2529	2671	3365
5 Years	2388	2769	1708	2186	1559	2593	2551	3043
6 Years	1823	2741	1646	2222	1584	2536	—	—
7 Years	1960	2341	1459	2121	1414	3770	—	—
8 Years	1688	2630	1432	2144	1501	2782	—	—
9 Years	1370	2236	1316	2277	1451	2596	—	—
Total (9 Years)	38 098	37 948	26 304	25 966	18 056	26 808	25 847	23 734

Table 3. Average incidence costs per patient by lower and higher stage cancer

	Age 18–64			Age ≥65		
	Stages 1–2	Stages 3–4	Difference	Stages 1–2	Stages 3–4	Difference
Colorectal (2010 £)						
3 Years pre	205	197	8	454	414	40
2 Years pre	267	257	10	453	491	–38
1 Year pre	998	1044	–46	1802	1714	88
1 Year	14 911	19 187	–4276	14 196	15 411	–1215
2 Years	3656	6417	–2761	3619	5143	–1524
3 Years	3069	4449	–1380	3034	4065	–1031
4 Years	2417	3670	–1252	2600	3273	–673
5 Years	2195	2676	–481	2632	3089	–457
6 Years	1566	2272	–706	2655	2954	–300
7 Years	1620	2615	–995	2454	2038	416
8 Years	1502	2051	–549	2671	2523	148
9 Years	1323	1472	–150	2305	2054	252
Total (9 Years)	33 728	46 306	12 577	38 876	43 170	4294
Breast (2010 £)						
3 Years pre	163	162	–2	433	501	68
2 Years pre	171	258	87	376	468	92
1 Year pre	464	607	143	1086	1324	238
1 Year	10 746	13 315	2569	7597	8804	1207
2 Years	3357	5785	2429	2529	3650	1121
3 Years	1953	3782	1829	2156	3170	1014
4 Years	1627	2932	1305	2230	2924	693
5 Years	1617	2841	1225	2077	2957	880
6 Years	1547	2645	1099	2174	2783	609
7 Years	1394	2618	1225	2063	2903	840
8 Years	1376	2559	1183	2134	2454	320
9 Years	1279	1848	569	2204	2932	728
Total (9 Years)	25 693	39 353	13 659	27 059	34 871	7812

Table 4. Health-care services accessed by patients with lower and higher stage cancer

	Age 18–64			Age ≥65		
	Stages 1–2	Stages 3–4	Difference	Stages 1–2	Stages 3–4	Difference
Colorectal						
Surgery in first 12 months	69.22%	56.28%	12.94%	60.03%	46.55%	13.48%
Total bed days first 12 months	14.36	17.02	–2.65	18.91	20.21	–1.30
Number of admissions						
Ordinary elective	1.13	1.21	–0.08	0.94	0.84	0.10
Ordinary emergency	0.64	1.17	–0.52	0.72	1.02	–0.31
Day case/regular	3.63	7.18	–3.56	1.68	3.54	–1.86
Outpatient	10.35	13.43	–3.08	7.26	8.84	–1.58
Breast						
Surgery in first 12 months	80.48%	69.98%	10.50%	65.97%	42.37%	23.60%
Total bed days first 12 months	4.28	7.22	–2.93	6.50	11.10	–4.61
Number of admissions						
Ordinary elective	1.10	1.06	0.04	0.83	0.60	0.23
Ordinary emergency	0.36	0.68	–0.31	0.34	0.63	–0.29
Day case/regular	3.72	5.33	–1.61	1.06	1.38	–0.32
Outpatient	16.24	16.65	–0.42	11.18	10.40	0.78

≥65 (or –7.9%). The total difference in cost 9 years after diagnosis equals to –£12 577 per patient age 18–64 as compared with –£4294 per patient age ≥65. In breast cancer, lower stage diagnosis is associated with –£2569 lower costs per patient age 18–64 in the first year of diagnosis (or –19.3% of first year costs) as compared with –£1207 cost per patient age ≥65 (or –13.7% of first year costs). The total difference in cost 9 years after diagnosis equals to –£13 659 per patient age 18–64 as compared with –£7812 per patient age ≥65. Differences in the cost of care between lower and higher staging 2–3 years before the diagnosis are small both in colorectal and breast cancer. This suggests that

much of the differences in costs emerging after the diagnosis are explained by differences in cancer staging.

Table 4 shows the differences in the type of care accessed by patients with lower and higher stage colorectal and breast cancer. Patients with lower stage colorectal and breast cancer are more likely to receive surgery within 12 month from their diagnosis with a positive impact on costs. However, they experience shorter hospital stay and a lower number of emergency admissions, day cases and outpatient visits within 12 month of diagnosis. These factors tend to reduce costs and are likely to explain the difference in cost reported in Table 3.

Phase of care costs. Figure 1 reports average monthly hospital costs in cohorts of patients surviving 12–13 months, 24–25 months, 36–37 months, 48–49 months and 60–61 months from diagnosis. Costs are close to zero before diagnosis with a progressive rise in the three months before and a stark increase in the month of diagnosis. The highest average monthly costs are observed in the months immediately following diagnosis (the ‘initial’ phase) and in the months immediately preceding death (the ‘terminal’ phase).

Prevalence costs. Table 5 reports 5-year cancer prevalence costs in 2010 for patients with a cancer diagnosis occurring up to 5 years before. We calculate costs separately for patient age 18–64 and ≥65 and partition costs by phases of care (initial, continuum and terminal). We also compare costs in patients with cancer to costs in a similar population without cancer.

The highest 5-year prevalence costs are generated by colorectal patients age ≥65 (£459m), followed by breast cancer patients age 18–64 (£426m), prostate cancer age ≥65 (£290m) and lung cancer age ≥65 (£267m). The comparison groups allow us to estimate the additional health-care cost that is due to the cancer condition, rather than to the other characteristics of patients with cancer, for example, their age. After subtracting the costs in the comparison group, prostate cancer is associated with the lowest prevalence

costs both in the population of patients age 18–64 (£56m) and age ≥65 (£104m) suggesting that most of the costs are due to the age of these patients, rather than cancer. Colorectal cancer is still the most expensive in the population of patients age ≥65, although net costs after subtracting comparison group costs are noticeably lower (£329m), followed by lung cancer (£193m) and breast (£134m). Breast cancer is the most expensive in the population of patients age 18–64 (£371m) followed by colorectal (£195m) and lung (£114m) cancer.

Differences in phase-specific costs are observed across examined cancers. Initial, continuum and terminal phases cover a similar share of costs for colorectal cancer for patients age ≥65. Initial phase costs absorb a large share of the total cost of care delivered to patients with colorectal cancer due to high incidence (new cases diagnosed every year) and high costs of surgical intervention that follows the diagnosis as displayed in Figure 1. Costs in the continuum phase absorb a greater proportion of prevalence costs relative to costs in the initial and terminal phases for prostate and breast cancer due to a larger proportion of these patients surviving the initial phase and not entering the terminal phase. Terminal costs contribute by far the largest share to lung cancer costs owing to poor survival and a large proportion of patients dying in the year of their diagnosis.




Figure 1. Patient average monthly costs: partitioned by survivals.

Table 5. Five-year prevalence costs in selected cancer sites, 2010

	Colorectal (2010 £,000s)		Breast (2010 £,000s)		Prostate (2010 £,000s)		Lung (2010 £,000s)	
	18–64	≥65	18–64	≥65	18–64	≥65	18–64	≥65
Initial	78 520	172 014	164 877	88 838	28 213	62 187	34 037	60 367
Continuum	85 883	139 380	223 635	104 489	45 871	144 476	14 395	23 474
Terminal	52 146	147 293	38 173	55 531	9 579	83 827	76 685	183 253
Total health-care costs (A)	216 549	458 688	426 685	248 858	83 663	290 490	125 117	267 095
Comparison group costs (B)	21 351	129 439	55 994	114 716	27 777	186 052	11 414	73 599
Net health-care costs (A–B)	195 198	329 249	370 691	134 142	55 886	104 438	113 703	193 496

DISCUSSION

This study expands the scope of existing population-based, patient-level data to the analysis of the costs of care accessed by patients with cancer in England. We combined the most granular cost information available from the NSRC with the NCDR-HES database creating a new resource for the analysis of the cost of cancer similar to the well-established SEER-Medicare database in USA. We processed millions of data records and reconstructed the patient care pathway retrospectively for each cancer patient in our sample. The new database has the potential to support a generation of new research in a similar vein to the success of SEER-Medicare producing much needed evidence to achieve the efficient allocation of current and future health resources to the care of patients with cancer.

We used the new NCDR-HES-RC database to estimate incidence costs, phase-specific costs and prevalence costs for the main four cancers in England. We were able to compare costs in the population of patients age 18–64 and ≥ 65 years old. Because of the lack of appropriate data, there is little evidence of the costs of care in the former age group both nationally and internationally. We examined costs by staging, before and after the cancer diagnosis, and in a comparison population of similar patients without cancer. We find evidence that the increment in the cost of care after a cancer diagnosis is markedly higher in patients age 18–64 as compared with patients age ≥ 65 across the four cancers examined. This is likely to be explained by the higher probability of receiving surgery for patients in the 18–64 age group. Health-care costs reduces dramatically after the first year and more markedly in patients age 18–64 who consume less resources 3 years after diagnosis as compared with patients age ≥ 65 . However, costs do not return to pre-diagnosis levels even 9 years after diagnosis in both age groups. We also find evidence that a lower stage diagnosis (stages 1–2) is associated with markedly lower costs as compared with a higher stage diagnosis (3–4) in patients with colorectal and breast cancer for whom sufficient data on staging were available. Although lower staging is associated with higher prevalence of surgery which may increase costs, we also find evidence that lower staging is also associated with shorter in-hospital stay, lower number of emergency admissions and outpatient visits, which are likely to reduce costs. Our findings suggest that an earlier diagnosis can generate substantial savings for the health system and even larger savings if achieved in the population of patients age 18–64. The younger patients are more likely to get surgery and also more likely to get offered chemotherapy, which might explain the broader scope for cost savings. Our evidence can be used to support existing health interventions aiming at improving the earlier diagnosis of cancer, such as the urgent GP referrals for patients with suspect cancer (National Institute for Health and Care Excellence, 2015) and the colorectal and breast cancer screening programs.

We identified the costs associated with the initial, the continuum and the terminal phase of the care pathway. We found evidence that the cost curve follows a 'U' shape distribution with high cost in the initial phase (first 6 months from diagnosis) and the terminal phase (last 12 months preceding death) and relatively low costs during the continuum phase similar to other studies (Riley *et al*, 1995; Brown *et al*, 1999, 2002; Yabroff *et al*, 2008b, 2011).

Finally, we calculate the additional costs of care due to cancer by comparing costs in examined cancer cohort with appropriate comparison groups of individuals without cancer. We elicited the amount of resources used by cancer patients because of their health condition from the resources used by the same patients because of their age and gender. This calculation provides a snapshot of the total costs to the health system of the care provided to cancer

patients every year excluding the costs that would be incurred had these people been cancer free. We estimate that colorectal cancer costed £542 million to the health system in 2010 due to hospital care, breast cancer £504 million, lung cancer £307 million and prostate cancer £160 million. The total cost of the main four cancers to the health system amounts to £1.5 billion in 2010, namely $\sim 3.0\%$ of the total cost of hospital care in England (£47.3 billion). Most of the existing studies do not elicit the cost of cancer from the cost of providing care to the cancer population in absence of cancer making it difficult to assess the impact of the disease on the resources of the health system. Our evidence provides an additional support to well-established evidence on the health outcomes of the population living with cancer and helps in making informed decisions on the financial scope of health interventions.

Study limitations. Our study presents a number of limitations due to the secondary data sources used in the analysis; most of these limitations are expected to fade away as the quality of the data collected in the HES, NCDR and NSRC improves over time and new data are added to existing sources. Firstly, our analysis does not include the costs of primary care, and social care services since data on utilisation and costs of these services are not available for the whole population of patients examined in this study. Other studies estimate that primary care and social care costs are a really small proportion of total care cost in patients with cancer (Luengo-Fernandez *et al*, 2013; Nuffield Trust, 2014).

Secondly, the NCDR data used in our analysis does not report cancer staging for a large share of patients in our sample reducing our ability to investigate the impact of staging on costs. We were able to use imputation techniques to estimate staging in colorectal and breast cancer, but we could not replicate this exercise in prostate and lung cancer due to insufficient data on staging recorded. However, Cancer Registries in England are making noticeably progress towards the collection of complete staging information for all cancers and the new release of NCDR data comes with more complete data on staging.

Finally, the quality of the cost information reported in the NSRC is variable across different hospitals and over time. We mitigate variation in data quality by using costs reported at a fixed point in time (2010), by excluding outliers, and calculating weighted averages of the costs of similar services reported by different hospitals (details included in Supplementary Appendix 3). Although measurement error is reduced using these techniques, information on cost variation across hospitals and over time is lost. Following recommendations from the Department of Health, an increasing number of hospitals are adopting a more sophisticated system to collect cost information at the level of patient; 50% of NHS hospital trusts used the new system at the time of our analysis. The diffusion of the new costing system will improve the quality of the NSRC data allowing for more granular cost analyses to be performed in the future.

Future research. The NCDR-HES-RC database offers numerous opportunities for future research. Our analysis is limited to data on utilisation of care in 2006–2010 as these were the most recent years of data available at the time of our study. As more data become available, new research could be devoted to assess the impact of the diffusion of new technologies on the cost of care, such as robotic radical prostatectomy. New studies could examine geographical variation in the cost of care and provide evidence on the impact of variation in medical practice and need of care. Finally, new research could be devoted to assess the impact of different pathways of care to costs, such as different routes that lead to a cancer diagnosis.

Improving the quality and the scope of the NCDR-HES-RC database will be crucial in fostering the new research.

ACKNOWLEDGEMENTS

We are grateful to the research staff at the National Cancer Intelligence Network within Public Health England and Macmillan Cancer Support for their useful comments on this report and support in accessing the data. We also thank Lucy Irvine (Public Health England), Sean McPhail (Public Health England), Ranjeeta Thomas (Imperial College London) and Paolo Li Donni (University of Palermo) for useful comments to the analysis. The views expressed are ours and not necessarily those of Macmillan. This work was supported by Macmillan Cancer Support (Grant number: 4644727). Funders had no active role in any stage of the research.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Basu A, Manning WG (2010) Estimating lifetime or episode-of-illness costs under censoring. *Health Econ* **19**: 1010–1028.
- Blakely T, Atkinson J, Kvizhinadze G, Wilson N, Davies A, Clarke P (2015) Patterns of cancer care costs in a country with detailed individual data. *Med Care* **53**: 302.
- Brown ML, Riley GF, Potosky AL, Etzioni RD (1999) Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. *Med Care* **37**: 1249–1259.
- Brown ML, Riley GF, Schussler N, Etzioni R (2002) Estimating health care costs related to cancer treatment from SEER-Medicare data. *Med Care* **40**: IV–104.
- Coupland VH, Konfortion J, Jack RH, Linklater KM (2011) *Data quality and completeness report*. Upper gastrointestinal site specific clinical reference group (SSCRG). National Cancer Intelligence Network. Available at: <http://goo.gl/mcJ0iO> (accessed on 17 March 2016).
- Hall PS, Hamilton P, Hulme CT, Meads DM, Jones H, Newsham A, Marti J, Smith AF, Mason H, Velikova G, Ashley L, Wright P (2015) Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data. *Br J Cancer* **112**: 948–956.
- Hirano K, Imbens GW (2001) Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. *Health Serv Outcomes Res Methodol* **2**: 259–278.
- Incisive Health (2014) Saving lives averting costs: an analysis of the financial implications of achieving earlier diagnosis of colorectal, lung and ovarian cancer. A report prepared for Cancer Research UK. Available at: <http://www.incisivehealth.com/uploads/Saving%20lives%20averting%20costs.pdf> (accessed on 27 October 2015).
- Luengo-Fernandez R, Leal J, Gray A, Sullivan R (2013) Economic burden of cancer across the European Union: a population-based cost analysis. *Lancet Oncol* **14**: 1165–1174.
- Maddams J, Utley M, Müller H (2012) Projections of cancer prevalence in the United Kingdom, 2010–2040. *Br J Cancer* **107**: 1195–1202.
- Martin S, Rice N, Smith PC (2008) Does health care spending improve health outcomes? Evidence from English programme budgeting data. *J Health Econ* **27**: 826–842.
- National Audit Office (2015) Progress in improving cancer services and outcomes in England Report by the Comptroller and Auditor General. HC 949 Session 2014–15. Available at: <https://www.nao.org.uk/wp-content/uploads/2015/01/Progress-improving-cancer-services-and-outcomes-in-England.pdf> (accessed on 17 March 2016).
- National Institute for Health and Care Excellence (2015) Suspected cancer: recognition and referral. Available at: <http://www.nice.org.uk/guidance/ng12/evidence/full-guidance-65700685> (accessed on 24 August 2015).
- Nuffield Trust (2014) Use of health and social care by people with cancer. Nuffield Trust. Available at: http://www.nuffieldtrust.org.uk/sites/files/nuffield/140602_social_care_for_cancer_survivors_full_report.pdf (accessed on 17 March 2016).
- Riley GF, Potosky AL, Lubitz JD, Kessler LG (1995) Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. *Med Care* **33**: 828–841.
- Sullivan R, Peppercorn J, Sikora K, Zalberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M (2011) Delivering affordable cancer care in high-income countries. *Lancet Oncol* **12**: 933–980.
- Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML (2008) Evaluation of trends in the cost of initial cancer treatment. *J Natl Cancer Inst* **100**: 888–897.
- Wooldridge JM (2007) Inverse probability weighted estimation for general missing data problems. *J Econ* **141**: 1281–1301.
- Yabroff KR, Bradley CJ, Mariotto AB, Brown ML, Feuer EJ (2008a) Estimates and projections of value of life lost from cancer deaths in the united states. *J Natl Cancer Inst* **100**: 1755–1762.
- Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML (2008b) Cost of Care for Elderly Cancer Patients in the United States. *J Natl Cancer Inst* **100**: 630–641.
- Yabroff KR, Lund J, Kepka D, Mariotto A (2011) Economic burden of cancer in the United States: estimates, projections, and future research. *Cancer Epidemiol Biomark Prev* **20**: 2006–2014.
- Yabroff KR, Warren JL, Schrag D, Mariotto A, Meekins A, Topor M, Brown ML (2009) Comparison of approaches for estimating incidence costs of care for colorectal cancer patients. *Med Care* **47**: S56–S63.



This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)